PharmaEngine (4162) Fundamentals 2026 — P/E 23.3x, Revenue Analysis | SniperIQ
PharmaEngine (4162) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$9.8B, trading at NT$68.40 on the TWO. This SniperIQ fundamentals page covers PharmaEngine's valuation (P/E 23.3x, P/B 1.9x), profitability (net margin 43.8%), revenue (NT$911M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PharmaEngine's market cap?
PharmaEngine (4162) has a market capitalization of approximately NT$9.8B, trading at NT$68.40 on the TWO. Market cap moves with the live share price.
What is PharmaEngine's P/E ratio?
PharmaEngine's trailing twelve-month P/E ratio is 23.3x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PharmaEngine?
PharmaEngine runs a net profit margin of 43.8%, a gross margin of 94.1%, and an operating margin of 48.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PharmaEngine generate?
PharmaEngine reported revenue of NT$911M for fiscal year 2025, with net income of NT